Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2024

Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2024 – By Drug Type (Talazoparib, Veliparib, Olaparib, Other Drug Types), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Ovarian Cancer, Breast Cancer, Other Applications), By End Users (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2024

Starting Price : $5000.00 | Pages : 175 | Published : June 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Definition And Segments

Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death.

The main drug types of poly ADP-ribose polymerase (PARP) inhibitor are talazoparib, veliparib, olaparib, and others. Talazoparib refers to a potent PARP inhibitor utilized in cancer therapy by disrupting DNA repair mechanisms in cancer cells. These are sold through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others. These inhibitors have found applications in ovarian cancer, breast cancer, and others and are used by several end users, such as hospitals, homecare, specialty clinics, and others.

The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –

1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Ovarian Cancer, Breast Cancer, Other Applications

4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from 7.52 billion in 2023 to $8.39 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy.

The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends in the forecast period include precision medicine, immunotherapy advancements, targeted therapies, artificial intelligence in drug discovery, and patient-centric healthcare.

Surging Prevalence Of Ovarian Cancer Fuels Growth In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

The increasing prevalence of ovarian cancer is expected to propel the growth of the poly ADP-ribose polymerase (PARP) inhibitor market going forward. Ovarian cancer refers to a malignant tumor that develops in one or both of a woman's ovaries, which are part of the female reproductive system responsible for producing eggs and female hormones. Ovarian cancer is growing due to impact of genetic predisposition, an aging population, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors are used in ovarian cancer treatment to target DNA repair mechanisms, specifically in patients with BRCA mutations, leading to synthetic lethality and enhanced tumor cell death. For instance, in February 2022, according to the World Ovarian Cancer Coalition, a Canada-based non-profit organization, ovarian cancer impacted 3.13 million women globally in 2020, and it's projected to rise by 42% to reach 4.4 million by 2040. Further, over the same period, there's expected to be a 51% surge in ovarian cancer-related deaths, climbing from 2.07 in 2020 to 3.13 in 2040. Therefore, the increasing prevalence of ovarian cancer is driving the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc

Tailored Therapy For Genetic Mutation-Driven Cancers

Major companies operating in the poly ADP-ribose polymerase (PARP) inhibitor market are developing generic PARP inhibitors to offer a tailored treatment approach for cancer patients with specific genetic mutations. Generic PARP inhibitors are medications that block the activity of the enzyme poly ADP-ribose polymerase (PARP). For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib, a PARP inhibitor under the IBYRA brand, aiming to enhance accessibility to advanced cancer treatment. IBYRA targets specific genetic mutations found in breast, ovarian, prostate, and pancreatic cancers, offering a tailored and effective treatment approach. The drug is particularly beneficial for patients with HRD-positive or BRACA mutations, helping to delay disease progression.

Ariceum Therapeutics Expands Radiopharmaceutical Portfolio Through Acquisition Of Theragnostics Ltd.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. With this acquisition, Ariceum Therapeutics significantly enhanced its radiopharmaceutical portfolio, gaining access to novel PARP inhibitor radiation therapies. Theragnostics Ltd. is a UK-based biotechnology company that develops radio-labeled PARP inhibitors to diagnose and treat tumors.

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The poly ADP-ribose polymerase (PARP) inhibitor market consists of revenues earned by entities by providing services such as diagnostic tests, clinical trials, consulting services, and patient support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The poly ADP-ribose polymerase (PARP) inhibitor market also includes sales of test kits, laboratory equipment, imaging systems, sample processing instruments, reagents, and chemicals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The poly ADP-ribose polymerase (PARP) inhibitor market research report is one of a series of new reports from The Business Research Company that provides poly ADP-ribose polymerase (PARP) inhibitor market statistics, including poly ADP-ribose polymerase (PARP) inhibitor industry global market size, regional shares, competitors with a poly ADP-ribose polymerase (PARP) inhibitor market share, detailed poly ADP-ribose polymerase (PARP) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the poly ADP-ribose polymerase (PARP) inhibitor industry. This poly ADP-ribose polymerase (PARP) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $8.39 billion
Revenue Forecast In 2033 $13.13 billion
Growth Rate CAGR of 11.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Characteristics

    3. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Trends And Strategies

    4. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size and Growth

    5.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Segmentation

    6.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Talazoparib

    Veliparib

    Olaparib

    Other Drug Types

    6.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Online Pharmacy

    Retail Pharmacy

    Other Distribution Channels

    6.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Ovarian Cancer

    Breast Cancer

    Other Applications

    6.4. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Homecare

    Specialty Clinics

    Other End Users

    7. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Regional And Country Analysis

    7.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    8.1. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    9.1. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    9.2. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    10.1. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    11.1. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    11.2. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    12.1. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    13.1. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    14.1. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    14.2. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    15.1. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    15.2. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    16.1. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    17.1. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    18.1. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    19.1. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    20.1. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    21.1. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    21.2. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    22.1. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    23.1. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    23.2. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    24.1. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    24.2. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    25.1. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    25.2. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    26.1. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    26.2. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    27.1. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    28.1. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    28.2. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    29.1. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

    29.2. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Landscape And Company Profiles

    30.1. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Landscape

    30.2. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Johnson & Johnson Services Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. AbbVie Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Bayer AG

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Novartis AG

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Other Major And Innovative Companies

    31.1. Sanofi S.A.

    31.2. AstraZeneca plc

    31.3. GlaxoSmithKline plc.

    31.4. Takeda Pharmaceutical Company Limited

    31.5. Merck KGaA

    31.6. Teva Pharmaceutical Industries Ltd.

    31.7. Daiichi Sankyo Company Limited

    31.8. Eisai Co. Ltd.

    31.9. Ipsen Biopharmaceuticals Inc.

    31.10. Genentech Inc.

    31.11. BioMarin Pharmaceutical Inc.

    31.12. Seattle Genetics Inc.

    31.13. Medivation Inc.

    31.14. Myriad Genetics Inc.

    31.15. PharmaMar S.A.

    32. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Benchmarking

    33. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

    35. Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Future Outlook and Potential Analysis

    35.1 Poly ADP-Ribose Polymerase (PARP) Inhibitor Market In 2028 - Countries Offering Most New Opportunities

    35.2 Poly ADP-Ribose Polymerase (PARP) Inhibitor Market In 2028 - Segments Offering Most New Opportunities

    35.3 Poly ADP-Ribose Polymerase (PARP) Inhibitor Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Pfizer Inc. Financial Performance
  • Table 76: Johnson & Johnson Services Inc. Financial Performance
  • Table 77: AbbVie Inc. Financial Performance
  • Table 78: Bayer AG Financial Performance
  • Table 79: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Pfizer Inc. Financial Performance
  • Figure 76: Johnson & Johnson Services Inc. Financial Performance
  • Figure 77: AbbVie Inc. Financial Performance
  • Figure 78: Bayer AG Financial Performance
  • Figure 79: Novartis AG Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
HER2 Inhibitors Global Market Report 2024 – By Treatment (Monotherapy, Combination Therapy), By Application (Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Other Applications), By End User (Hospitals, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Checkpoint Inhibitors Global Market Report 2024 – By Drug (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Other Drugs), By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications), By End-Users (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Protein Inhibitors Global Market Report 2024 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2024 – By Drugs Type (Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea, Other Drug Types), By Route Of Administration (Oral, Intravenous, Intravitreal), By Application (Oncology, Ophthalmology, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
TNF Alpha Inhibitors Global Market Report 2024 – By Drug (Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)), By Route Of Administration (Oral, Subcutaneous, Intravenous, Other Route Of Administration), By Disease Type (Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Interleukin Inhibitors Global Market Report 2024 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6, Other Types), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
ACE Inhibitors Global Market Report 2024 – By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents), By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs), By Dosage Form (Oral Tablets, Oral Solutions), By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications), By End-Users (Hospitals, Online Drug Stores, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024 – By Product (Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications), By End-Users  (Hospitals, Specialty Clinics, Academic and Research Institutions) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the poly adp-ribose polymerase (PARP) inhibitor market?

Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death. For further insights on the poly adp-ribose polymerase (PARP) inhibitor market, request a sample here

How will the poly adp-ribose polymerase (PARP) inhibitor market drivers and restraints affect the poly adp-ribose polymerase (PARP) inhibitor market dynamics? What forces will shape the poly adp-ribose polymerase (PARP) inhibitor industry going forward?

The poly adp-ribose polymerase (PARP) inhibitor market major growth driver - Surging Prevalence Of Ovarian Cancer Fuels Growth In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market. For further insights on the poly adp-ribose polymerase (PARP) inhibit request a sample here

What is the forecast market size or the forecast market value of the poly adp-ribose polymerase (PARP) inhibitor market?

The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from 7.52 billion in 2023 to $8.39 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy. The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends in the forecast period include precision medicine, immunotherapy advancements, targeted therapies, artificial intelligence in drug discovery, and patient-centric healthcare. For further insights on the poly adp-ribose polymerase (PARP) inhibitor market, request a sample here

How is the poly adp-ribose polymerase (PARP) inhibitor market segmented?

The poly adp-ribose polymerase (PARP) inhibitor market is segmented
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End UsersFor further insights on the poly adp-ribose polymerase (PARP) inhibitor market, request a sample here

Which region has the largest share of the poly adp-ribose polymerase (PARP) inhibitor market? What are the other regions covered in the report?

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the poly adp-ribose polymerase (PARP) inhibitor market, request a sample here.

Who are the major players in the poly adp-ribose polymerase (PARP) inhibitor market?

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc For further insights on the poly adp-ribose polymerase (PARP) inhibitor market, request a sample here.

What are the key trends in the poly adp-ribose polymerase (PARP) inhibitor market?

Major trend in the poly adp-ribose polymerase (PARP) inhibitor market - Tailored Therapy For Genetic Mutation-Driven Cancers. For further insights on the poly adp-ribose polymerase (PARP) inhibitor market, request a sample here.

What are the major opportunities in the poly adp-ribose polymerase (PARP) inhibitor market? What are the strategies for the poly adp-ribose polymerase (PARP) inhibitor market?

For detailed insights on the major opportunities and strategies in the poly adp-ribose polymerase (PARP) inhibitor market, request a sample here.

How does the poly adp-ribose polymerase (PARP) inhibitor market relate to the overall economy and other similar markets?

For detailed insights on poly adp-ribose polymerase (PARP) inhibitor market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the poly adp-ribose polymerase (PARP) inhibitor industry?

For detailed insights on the mergers and acquisitions in the poly adp-ribose polymerase (PARP) inhibitor industry, request a sample here.

What are the key dynamics influencing the poly adp-ribose polymerase (PARP) inhibitor market growth? SWOT analysis of the poly adp-ribose polymerase (PARP) inhibitor market.

For detailed insights on the key dynamics influencing the poly adp-ribose polymerase (PARP) inhibitor market growth and SWOT analysis of the poly adp-ribose polymerase (PARP) inhibitor industry, request a sample here.